Course Provider
COMPASS Pathways is a UK-listed biopharmaceutical company developing COMP360 synthetic psilocybin therapy for treatment-resistant depression, with two successful Phase 3 trials making it the leading candidate for the first regulatory approval of a classic psychedelic medicine.
COMPASS Pathways is best understood as a serious clinical-development company rather than a broad public training school. Its therapist programme appears to have been built for regulated trial delivery and commercial readiness, with a notable evidence-based lineage and input from established academics and clinicians in psychology, psychiatry and psychedelic research. In the field, that gives it credibility and structure, but also means it is most relevant to professionals operating in formal healthcare or research settings rather than to general interest learners.
Best suited to licensed clinicians and clinical-research staff who are involved, or expect to be involved, in psilocybin-assisted therapy delivery within regulated settings. It is less obviously aimed at the curious public or at standalone facilitators outside medical systems.
The materials support that therapists are employed by clinical trial sites and that the programme is for healthcare professionals working in psilocybin therapy. Specific licensure or entry requirements are not clearly stated in the sources reviewed.
Compass says the therapist training programme was published in a peer-reviewed paper in Frontiers in Psychiatry, and its materials describe it as designed by experts and approved by the FDA for research purposes. I did not find clear evidence of formal third-party accreditation, CME, or CE credit for the programme in the sources reviewed.
No public tuition pricing was found. For the research context, Compass states it provides cGMP COMP360 psilocybin to researchers free of charge, while researchers cover packaging and shipping. That appears separate from any therapist training cost, which was not disclosed.
Learners appear to gain a structured competency framework for supporting preparation, dosing and integration sessions in COMPASS-sponsored psilocybin research, with mentoring and professional development. The practical outcome is readiness to work on clinical trials or, more broadly, within Compass-aligned psilocybin care pathways.
Linked Courses
3
Active Listings
1
Primary Formats
Hybrid, Self-paced
Programs linked directly to this provider in the Blossom course dataset.
By COMPASS Pathways
The COMPASS Therapist Training Programme provides evidence-based training for mental health professionals working with COMP360 psilocybin therapy. It combines online theory, in-person practical skills training, and ongoing mentoring.
Next cohort: Jul 13, 2026
By COMPASS Pathways
This page summarises results from COMPASS Pathways' phase 2b trial of investigational COMP360 psilocybin treatment for treatment-resistant depression. The study assessed three doses and reported a significant reduction in depressive symptoms after 25mg with psychological support.
By COMPASS Pathways
An overview of investigational psilocybin therapy and how it is being studied for mental health conditions. It explains the treatment process, including preparation, the dosing session, and integration.
No medicine self-experience listed
Reference points selected from shared training modalities, learner audience, level, delivery format, pricing, and location.